INTRODUCTION
Monogenic DM, which is associated with a single-gene disorder or hereditary diseases [1,2]. The most common form of monogenic diabetes is maturity-onset diabetes of the young (MODY), and this category also includes neonatal diabetes and maternally inherited diabetes and deafness [3]. MODY has similar charicteristics to those of type 1 and 2 DM, resulting in diagnostic ambiguity. In addition, disease treatment and progression differ between the two conditions, further emphasizing the importance of an accurate differential diagnosis [4,5]. Recently, there has been an explosion in research related to the genetic diagnosis of monogenic DM using targeted panel exome sequencing, leading to the identification of 14 MODY-specific genetic variants that change the function of beta cells to cause DM [6-8]. However, studies on the genotype of monogenic DM have mainly focused on Caucasian patients, with limited genetic screening performed for Asian patients to date. Therefore we performed targeted panel exome sequencing on pediatric patients suspected of having monogenic DM at Kyungpook National University Children’s Hospital to determine how many Patients have MODY gene variation.
MATERIALS AND METHODS
Participants
Participants included pediatric patients from the Endocrinology Unit at Kyungpook National University Children’s Hospital who were receiving insulin therapy by injection following a diagnosis of DM prior to the age of 25 years. A total of 41 patients who have a family history of two generation or more were selected for targeted panel exome sequencing. Patients who received a diagnosis of type 1 DM (C-peptide <0.6 ng/mL, or anti-pancreas antibody-positive) were excluded from the study [9].
Clinical parameters and Targeted exome sequencing
Patient clinical characteristics were reviewd with respect to age, sex, family history, body mass index (BMI), and C-peptide levels. Targeted exome sequencing in the patient was performed using the TruSight One Sequencing Panel, 32 genes, including 14 identified MODYgenes (HNF4A, GCK, HNF1A, PDX1, HNF1B, NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8, KCNJ11, APPL1) and 18 monogenic DM-related genes (EIF2AK3, FOXP3, GATA4, GATA6, GLIS3, IER3IP1, INSR, MNX1, NEUROG3, NKX2-2, PAX6, PTF1A, RFX6, SLC19A2, PTPRD, SYT9, WFS1, and PAX1).The pathogenicity of the geneticvariants was evaluated according to the American College of Medical Genetics and Genomics and Association for Molecular Pathology guidelines.
RESULTS
The characteristics of participants (Table 1)
Table 1.
The characteristics of participants
| Variables | Patients | |
|---|---|---|
| Number (M/F) | 41 (23/18) | |
| Age | 11.8±3.7 | |
| HbA1c | ||
| At Diagnosis | 12.1±2.4 | |
| BMI (kg/m2) | 23.1±4.7 | |
| Post-meal | 10.7±9.8 | |
| Post-meal | 3.84±3.38 | |
Of the 41 patients, 23 were male (56.1%) and 18 were female (43.9%). At the time of diagnosis, the average age of all patients was 11.80±3.7 years, the HbA1c level was 12.14±2.42%, body weight was 59.95±26.92 kg, BMI was 23.11±4.72 kg/m2, serum insulin level before and after meals was 6.40±4.01 uU/mL and 10.72±9.83 uU/mL, respectively, and the serum level of C-peptide before and after meals was 2.50±1.61 ng/mL and 3.84±3.38 ng/mL, respectively.
Identification of gene variants (Table 2)
Table 2.
Clinical and molecular characteristics of patients with MODY gene variant
| Pt | Gen | Age (yr) | BMI | HbA1c | c pep | Gene | DNA | AA Change | Zyg | Disesase | Class | Clin | Novelity | In silico analysis score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 9.9 | 1.0 | 9.0 | 5.19 | HNF4A | c.778G>A | p.(Asp260Asn) | Het | MODY1 | VUS | none | S/P/M Deleterous |
|
| 2 | M | 3.2 | -0.43 | 6.7 | 0.42 | GCK | del (chr.44184714-44186245) | exon 9-11 | Het | MODY2 | PV | none | / | |
| 3 | F | 3.2 | 1.29 | 6.7 | 1.99 | GCK | c.775G>A | p. (Ala259Thr) | Het | MODY2 | PV | none | S/P/M Deleterous |
|
| 4 | M | 6.9 | 1.83 | 6.4 | 1.70 | GCK | c.579+1G>T | p.(?) | Het | MODY2 | PV | none | M Tolerate |
|
| 5 | F | 12.2 | 0.67 | 9.0 | 2.1 | HNF1A | c.773T>C | p.(leu258pro) | Het | MODY3 | VUS | none | Y | S/P/M Deleterous |
| 6 | M | 15.5 | 1.47 | 6.1 | 2.6 | CEL | c.1421C>T | p.(Thr474Met) | Het | MODY8 | VUS | none | S Deleterous P/M Tolerate |
|
| 7 | F | 13.3 | 1.35 | 13.2 | 1.61 | CEL | c.2106_2171del | p.(Thr7004_Val725del) | Het | MODY8 | VUS | none | / | |
| 8 | M | 10.1 | 1.75 | 14.7 | 1.47 | CEL | c.1154C>T | P.(Thr385Met) | Het | MODY8 | VUS | none | S/P Deleterous M Tolerate |
|
| 9 | M | 14.1 | 1.49 | 14.3 | 1.97 | CEL | c.1627C>T | p.(Arg543Cys) | Het | MODY8 | VUS | none | S/P Deleterous M Tolerate |
|
| 10 | M | 14.1 | 2.12 | 12.3 | 3.8 | PAX4 | p.(Arg121Trp) | p.(Arg 121 Trp) | Het | MODY9 | VUS | none | S/P/M Deleterous |
|
| 11 | M | 14.2 | 1.54 | 12.8 | 0.2 | PAX4 | c.374_412+1del | p.(Arg192His) | Het | MODY9 | LPV | none | Y | S/P Deleterous M polymorphism automatic |
| 12 | M | 10.2 | 1.36 | 17.3 | 1.0 | INS | c.67G>A | P.(Ala23Thr) | Het | MODY10 | VUS | deafness | S/P/M Tolerate |
|
| 13 | M | 14.2 | 1.55 | 12.4 | 4.0 | BLK | c.337del | p.(val113TrpfsTer52) | Het | MODY11 | VUS | none | / | |
| 14 | F | 11.2 | 1.71 | 13.0 | 3.3 | WFS1 | c.1846G>T | p.(Ala616Sat) | Het | WFS1 | VUS | none | S/P/M Tolerate |
|
| 15 | F | 14.2 | 0.35 | 11.6 | 1.1 | WFS1 | c.76C>T | P.(Arg26Ter) | Het | WFS1 | LPV | none | M Deleterous |
|
| 16 | M | 16.2 | 0.23 | 12.4 | 0.8 | WFS1 | c.2417C>G | p.(Ala806Gly) | Het | WFS1 | VUS | none | Y | S Tolerate P/M Deleterous |
| 17 | F | 16.2 | 1.74 | 12.6 | 2.0 | WFS1 | c.1264G>T | p.(Ala422Ser) | Het | WFS1 | VUS | none | S/M Deleterous P Tolerate |
|
| 18 | F | 17.2 | -0.51 | 10.3 | 1.2 | RFX6 | c.280G>C | p.(Asp94His) | Het | MTCHRS | VUS | none | S/M Deleterous P Tolerate |
|
| 19 | M | 17.2 | -0.01 | 11.8 | 1.3 | GLIS3 | c.838G>C | p.(Glu280Gln) | Het | Diabetes Mellitus |
VUS | none | Y | S/P/M Tolerate |
Pt, patient; Gen, Gender; Age, Age when DM diagnosis/exon sequencing did; BMI, Body mass index, Z score; C.pep, C-peptide; Zyg, zygomatic; Ds, disease; C.pep, C.peptide; Path, pathophysology; Het, heterozygosity; Clin, Clinical Pathology; VUS,variants of unknown significance; PV, pathogenic variants; LPV, likely pathogenic variants; WFS, wolfram-like sydrome; Y, novel variation; Zyg, zygonite; AA, aminoacid; in silico analysis S, SIFT; P, Polyphen2; M, MutationTaster.
Variants were identified in 19 of the 41patients (46.3%), including variants in seven MODY-identified genes (HNF4A, GCK, HNF1A, CEL, PAX4, INS, and BLK) and three monogenic DM-related genes (WFS1, RFX6, GLIS3).
DISCUSSION
In this study, targeted panel exome sequencing was performed on pediatric patients suspected of having monogenic DM. In a review of the literature, Kim et al. [10] confirmed that the MODY3 and MODY2 genotypes account for 20% and <5% of all MODY cases in Korea and China, respectively. In this study, monogenic DM variants were identified in 19 of 41 (46.3%) patients. Actually, the frequency of PV or LPV variations excluding the actual VUS is 9.75% (4 of 41), and the frequency of PV or LPV variations excluding the VUS variations is more reliable as the frequency of the actual Monogenic DM [11]. However, compared to studies where the previous VUS and PV/LPV ratios were 6% and 2.1%, respectively, we can see a high positive rate [12]. Instead, Yang et al. [13] reviewed studies of Korean patients with monogenic DM, highlighting that the prevalence of MODY, which has been studied mainly in Western populations to date, may be different for Asians. Similarly, we found a high prevalence of the MODY8 genotype (4/17, 21.0%), which has been reported at a low frequency in previous studies [14].
Based on a review of the state of monogenic DM in Korea, MODY exhibits various pathophysiological mechanisms and clinical manifestations [13]. Unlike type 1 DM, which is caused by the destruction of pancreatic beta cells, some MODY subtypes do not require insulin therapy and can be improved with oral antidiabetic medications, diet management, and treatment with sulfonylurea. However, we did not find any difference in disease progression according to the presence or absence of variants, with respect to a similar significant in HbA1c and BMI.
The limitation of this study were many patients with gene variants showed VUS. Further more, there are not many patient numbers. In order to secure these limitations in the future, it is necessary to conduct a family examination on patients with confirmed genetic variation, and increased targeted study numbers.
In conclusion, using targeted panel sequencing, we were able to make molecular genetic diagnoses for 17/39 patients (44%) with MODY. MODY variants were detected more than expected in Korean children and aldolescents with suspected monogenic DM.
ETHICAL STATEMENT This study was approved by the Institutional Review Board (approval number: 2017-05-006) of Kyungpook National University Children’s Hospital. This was a retrospective study; hence, it was exempted from the requirement of obtaining informed consent from patients.
AUTHOR CONTRIBUTIONS Conceptualization: Moon JE. Data curation: Lee JM and Lee SW. Formal analysis: Lee JM, Lee R, Lee MS, Lee SW, and Moon JE. Methodology: Moon JE. Writing - original draft: Lee SW, Lee JM, and Moon JE. Writing - review & editing: Lee JM and Moon JE.